TD Cowen analyst Ken Cacciatore lowered the firm’s price target on Biohaven (BHVN) to $15 from $50 and keeps a Buy rating on the shares. The firm said the CRL for Vyglxia is highly disappointing, and they are unsure if it will ever make it to market.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- 3 Best Stocks to Buy Now, 11/5/2025, According to Top Analysts
- FDA complete response letter cites issues in Biohaven Vyglxia NDA
- Biohaven Ltd.: Navigating Setbacks with Strategic Restructuring and Promising Pipeline
- Strategic Realignment and Pipeline Potential Drive Buy Rating for Biohaven Ltd.
- Video: What is dragging down Biohaven today